Professor Robert Clarke
MD, FRCP, FFPH, FFPHI, MSc, DCH
Professor of Epidemiology and Public Health Medicine
- Clinical Trial Service Unit and Epidemiological Studies Unit
Robert Clarke is a Professor of Epidemiology and Public Health Medicine at the Clinical Trial Service Unit (CTSU), Nuffield Department of Population Health, University of Oxford and Consultant in Public Health Medicine and Director of the MSc course in Global Health Science. He qualified in clinical medicine in Ireland and worked for 5 years in internal medicine and 4 years in cardiology. After 2 years in clinical pharmacology at Vanderbilt University, Nashville, USA, he joined CTSU in 1991 and specialised in Cardiovascular Epidemiology.
His main research interests are to understand the importance of classical and novel risk factors for occlusive vascular diseases. He led several large observational studies and meta-analyses of observational studies and randomized trials (eg, Whitehall study, PROCARDIS, CARDIoGRAMplusC4D, B-Vitamin Treatment Trialists’ Collaboration and the BEST-D trial). He also worked extensively on the Prospective Studies Collaboration and the China Kadoorie Biobank (CKB) study. He currently leads a research programme to assess the importance of blood pressure, blood lipids, and novel biomarkers (including genetic markers, cytokines, proteomics and metabolomics) for occlusive vascular diseases in the CKB study. His work has been widely cited (200 publications, H-index of 54) and is listed in Tomson Reuters’ Most Influential Scientific Minds 2014.
Lipoprotein(a) Levels and the Risk of Myocardial Infarction Among Seven Ethnic Groups.
Paré G. et al, (2019), Circulation
Adiposity in middle and old age and risk of death from dementia: 40-year follow-up of 19,000 men in the Whitehall study.
Allen AN. et al, (2019), Age Ageing
Blood Pressure and Risk of Subarachnoid Hemorrhage in China.
McGurgan IJ. et al, (2018), Stroke
Interethnic analyses of blood pressure loci in populations of East Asian and European descent.
Takeuchi F. et al, (2018), Nat Commun, 9
Metabolomic Consequences of Genetic Inhibition of PCSK9 Compared With Statin Treatment
Sliz E. et al, (2018), Circulation, 138, 2499 - 2512